Innovation in Oncology Drug Development

المؤلفون المشاركون

Huber, Matthew
Huber, Brian

المصدر

Journal of Oncology

العدد

المجلد 2019، العدد 2019 (31 ديسمبر/كانون الأول 2019)، ص ص. 1-16، 16ص.

الناشر

Hindawi Publishing Corporation

تاريخ النشر

2019-11-23

دولة النشر

مصر

عدد الصفحات

16

التخصصات الرئيسية

الأمراض
الطب البشري

الملخص EN

Significant progress has been made in our understanding of the molecular lesions responsible for tumor cells to exhibit uncontrolled growth while circumventing normal mechanisms of apoptosis and their ability to migrate and invade normal tissues while evading recognition and destruction by the immune system.

This understanding has enabled the development of therapies specifically targeted to these lesions coupled to innovative treatment regimens to most effectively use these new targeted therapies with precision in selected subpopulations of patients.

Innovation at the scientific and clinical levels has been appropriately embraced and supported at the FDA, resulting in regulatory innovation to facilitate and adapt to the Precision Medicine environment.

نمط استشهاد جمعية علماء النفس الأمريكية (APA)

Huber, Matthew& Huber, Brian. 2019. Innovation in Oncology Drug Development. Journal of Oncology،Vol. 2019, no. 2019, pp.1-16.
https://search.emarefa.net/detail/BIM-1184743

نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)

Huber, Matthew& Huber, Brian. Innovation in Oncology Drug Development. Journal of Oncology No. 2019 (2019), pp.1-16.
https://search.emarefa.net/detail/BIM-1184743

نمط استشهاد الجمعية الطبية الأمريكية (AMA)

Huber, Matthew& Huber, Brian. Innovation in Oncology Drug Development. Journal of Oncology. 2019. Vol. 2019, no. 2019, pp.1-16.
https://search.emarefa.net/detail/BIM-1184743

نوع البيانات

مقالات

لغة النص

الإنجليزية

الملاحظات

Includes bibliographical references

رقم السجل

BIM-1184743